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 The purpose of this paper is to present in details, an extended case-study 
focused on emerging in vitro Diagnostics Technology as reflected on retrieved and 
evaluated Industrial Property Documents. More specific, this study comprises of the 
state-of-the-art and the perspectives of automatic Immunoassay Analyzers, it follows 
the innovation patent-trail from Flow Cytometry to Quantum Dots applications in the 
in vitro Diagnostics of tomorrow and finally, it provides an overview of the trends in 
Next Generation Nucleic Acid and Protein Sequencing, all of them as depicted on 
numerous relevant, retrieved and processed Industrial Property Documents. 
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Introduction 
Innovation has become synonymous of competitiveness, however, the 
increasing importance for Industrial Property (IP) Rights, and more specific for 
Patent-information, is often disregarded in “academic” Biomedical Technology 
(BMT) and Medical Informatics (MI) R&D. We synopsize our activities to employ 
IP-Docs for the optimization of our BMT/MI-students training and participation in 
R&D activities.  
A course on IP-Rights for senior BMT and postgraduate MI-students[1] is 
being offered since 2003, addressing the origin and the historical development of IP-
protection, the essential features and the relevant aspects of the IP-core doctrines, 
BMT-equipment classification and information retrieval out of patent-documents, by 
employing the European Patent Office (EPO) esp@cenet search-engine[25] and their 
employment in R&D-projects. This “IP-Docs retrieval and evaluation project” is a 
unique, non-funded, R&D activity in Greece. It has led to about 20 publications, 
during the last 5 years [2-19] dealing with: 
 Development of “semantic” Patent-search techniques.   
 Confining the “state of the art” in contemporary Molecular Imaging.  
 IP-document based Review of 50 years Biomedical LASER Research. 
 IP trends in brain and spine implantable stimulators. 
 Manufacturers’ R&D-strategy for patients’ radiation-protection 
outlined in IP-Docs, 
The interest for this approach is corroborated by invitations for Lectures and 
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Tutorials in International Conferences (ITU, IAEA, WHO, IEEE/EMBC etc.) and 
encourages us to continue our efforts, supported only by our students. 
The purpose of this paper is to present in details, an extended case-study 
focused on emerging in vitro Diagnostics Technology as reflected on retrieved and 
evaluated Industrial Property Documents [20-23].  
More specific, this study comprises of the state-of-the-art and the perspectives 
of automatic Immunoassay Analyzers, it follows the innovation patent-trail from Flow 
Cytometry to Quantum Dots applications in the in vitro Diagnostics of tomorrow and 
finally, it provides an overview of the trends in Next Generation Nucleic Acid and 
Protein Sequencing, all of them as depicted on numerous relevant, retrieved and 
processed Industrial Property Documents. 
 
State-of-the-Art and perspectives of immunoassay analyzers as  reflected on IP-
documents   
Immunoassay is the method used for the detection of a Protein in a specimen through 
the inherent ability of an antibody to bind to the specific structure. From the pioneers 
Rosalyn Sussman Yalow and Solomon Berson, who described Radioimmunoassay 
(RIA) for the first time in 1959
[24]
 to present days, various tagging methods have been 
developed.  
It is the purpose of this presentation to contribute a retrospective view, regarding the 
evolution of immuno-analyzers, as reflected on Industrial Property (IP) documents.  
Figure 1. Temporal distribution of Immuno-Assay related IP-Documents (left: title, right: title and 
abstract search). 
 
Further, by focusing specific on the present trends of the rather dominant 
Chemiluminescence-Assays (CLIA), as depicted in relevant IP-Docs, to attempt to 
estimate CLIA’s future trends. 
The evaluation of relevant IP-Documents, retrieved by employing the on-line 
esp@cenet search-engine of the European Patent Office (EPO), attempted to create a 
mapping of the promising techniques and thus, a market-trend prediction, for the next 
years. 
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Figure 2. Distribution of Immuno-Assay related IP-Documents according to the country of origin (left) 
and according to the number of IP-Documents per main classification code (right). 
   
Figure 3. The US2013210166 (A1) application (left) and a schematic representation of a 20-position         
E-Chip for Multi Analyte Analysis described in the same document (right). 
 
In total, 82 Immuno-assay and 24 specific Chemiluminescence-assay related IP-
Documents have been retrieved and evaluated. A common absolute peak around the 
year 2011 indicates an increased R&D development in CLIA that is partially due to 
the introduction of electro-generated CLIA. About 46% of the applications have been 
filed in the Chinese Patent Office and 37% in the Japanese Patent Office, indicating 
an important shift towards the Asian markets. 
An indicative and promising patent application US2013210166 (A1): «Low-Cost 
Electrode Chip Variants and Methods for Multi Analyte Analysis and Referencing 
Based on Cathodic Electroluminescence» is presented in Figure 3. The claimed 
invention relates to electrode chip (E-Chip) cartridge devices, which are used in hot 
electron-induced electro-chemiluminescence (HECL) and electroluminescence (EL) 
methods and instrumentation, based on the electrical excitation of label molecules. 
The subsequent measurement of the luminescence enables the quantization of 
analytes’ concentrations in bio-affinity assays, especially outside of centralized 
laboratories, in rapid screening tests. 
The present situation of the in vitro Diagnostics (IVD) market shows a dominance 
trend for high-throughput CLIA-Analyzers. Other methods (RIA, ELISA, PFIA etc.) 
are still present, however, in smaller scale demands (small or specialized 
Laboratories).  
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This emerging picture is fully compatible with the retrospectively outlined trends of 
CLIA systems, compared to the overall Immuno-Assay systems trends. The physical 
advantages of Chemiluminescence Assays i.e. the stability of the effect and the high 
sensitivity due to the prompt “emission” of the total information is fully reflected 
upon the IP Documents evaluated. 
 
Following the innovation Patent-Trail from Flow Cytometry to Quantum Dots 
applications in the In Vitro diagnostics of tomorrow 
Fluorescence is being used in the IVD, as a non-destructive way of tracking or 
analyzing biological molecules, for over forty years. Both usually implementation 
methods i.e. first, auto-fluorescence (NADH, Tryptophan etc.) and second, "labeling” 
with extrinsic fluorescent (chemical dye, fluorescent protein or quantum dot), are 
employed to detect the Biomolecules under investigation.  
In this part of our project, the innovation trail has been reviewed first, by focusing 
mainly on Immuno-fluorescence and Cytometric Assays and second, by attempting to 
depict the future course of the emerging “Quantum Dots” labeling technology.  
The method to accomplish this task was to examine the development of these very 
important IVD-Techniques, as they are reflected on relevant Industrial Property (IP) 
Documents.  
It was attempted to create a patent-mapping of the promising techniques in these IVD-
areas and thus, to reveal probable market-trends, during the next 10 years. 
 
     
 
Figure 4. An excerpt of the Retrieved IP-Documents (left) and a typical search report of the EPO       
search-engine espa@cenet (right). 
 
During this IP-search, in total 36 Immunofluorescence, 74 Hybrid Hematology and 
Flow-Cytometry and 39 Quantum-Dots related IP-Documents have been retrieved and 
evaluated. The details of the retrieved IP-Documents are presented in Table 1 and in 
Figures 5-7. 
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Table 1. Details of the retrieved IP-Documents 
Fluorescence Polarization Assay 
Number of 
Patent Documents 
Data-Base Keywords Title Title & Abstract 
 
WWW 
Polarized Fluorescence Assay 0 29 










Polarized Fluorescence Assay 0 8 




Immuno-Fluorescence 0 0 
 
WIPO 
Polarized Fluorescence Assay 0 5 




Immuno-Fluorescence 1 2 
 
 
      
 
Figure 5. Number of relevant IP-Docs sorted by the Patent Office of origin. 
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Figure 6. Fluorescence Polarization Assay (FPA) 




Figure 7. Number of IP-Docs sorted by the applicant and as insert a promising Patent Application 
(US2011/0165603A1) claiming Fluorescence quench assay. 
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Figure 8. IP-Docs per year (left) and the numbers of IP-Docs filed per applicant (right) for Hematology 
analyzers published during the period 1976-2011. 
 
Another important field of applications of Fluorescence in the IVD is the Hybrid 
Hematology and Flow-Cytometry techniques. We have performed focused searches in 
the corresponding IPC/CPC subject-matter classes, and the numbers of IP-Docs per 
year, as well as, the numbers of IP-Docs filed per applicant, for Hematology analyzers 
published patent applications, for the period 1976-2011, are presented in Figure 8.  
 
      
 
Figure 9. Number of relevant IP-Docs sorted by the Patent Office of origin (left) and a recent and 
promising IP-Doc. (US2011254533A1) concerning coaxial illumination of Coulter Aperture (right) in 




Figure 10. An important granted Patent US6524858: Single channel single dilution detection 
method. 
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Figure 11. Numbers per year of “Quantum Dots” related Number IP-Docs for results concerning the 
application and the priority dates for the period 1998-2013 (left) and the numbers of relevant IP-Docs 
sorted by the Patent Office of origin for the same time period (right). 
 
 
The numbers of relevant IP-Docs, sorted by the Patent Office of origin and a recent 
Patent Application (US2011/254533A1), claiming a «Coaxial illumination of Coulter 
Aperture in full function Hematology Analyzer» are presented in Figure 9. 
Finally, an important granted Patent (US6524858) concerns a single channel single 
dilution detection method, for the identification and quantification of blood cells and 
platelets, in a whole blood sample using an automated hematology analyzer and itis 
presented in Figure 10.  
Endeavoring to depict the future course of the emerging “Quantum Dots” 
Fluorescence labeling technology, we have performed a rigorous search of related IP-
Docs. Quantum Dots Fluorescence is based on their remarkable physical principles 
that are resulting in their cardinal features of Photostability and Ligand exchange 
ability and only their potential Biotoxicity set limits to this emerging «magic» label. 
The most important results of the patent mapping are presented in Figures 11-13. 
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Figure 12. Number of relevant IP-Docs sorted by Applicant. 
 
 
     
Figure 13. Two promising IP-Docs: US2011/0235879 A1: Quantitative Multi-spectral Image 
Analysis of Tissue (left) and WO2010/1411052: Quantum Dot-sensory array for Biological 
recognition (right). 
 
The filing numbers per year, of “Quantum Dots” related IP-Docs, for the period 1998-
2013, for results concerning the application and the priority dates, are presented in 
Figure 11 (left). The results refer to both, the application and the priority dates of the 
filed patent documents.  
The numbers of relevant IP-Docs sorted by the Patent Office of origin, for the same 
time period, are also presented in Figure 11 (right). Almost 50% of the IP-Docs have 
been filed China, about 20% in the USA, 20% in WIPO (World Intellectual Property 
Organization), 5% in EPO and 5% in Korea, proving the constant displacement of the 
Industrial Property activities towards Asia, even in emerging Technologies. 
Figure 12 displays the number of “Quantum Dots” relevant IP-Docs, sorted by 
Applicant. The graph corroborates the increasing importance of Asia in «technology 
stock-exchange» and successfully individualizes the most important Chinese 
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stakeholders in this scientific-industrial field. 
Finally, two promising IP-Docs, the first (US2011/0235879 A1) claiming a 
«Quantitative Multi-spectral Image Analysis of Tissue Specimens Stained with 
Quantum Dots» and the second (WO2010/1411052) disclosing a «Quantum Dot-
sensory array for Biological recognition» are presented in Figure 13.  
An absolute maximum and plateau is achieved for Immuno-fluorescence related IP-
Documents number between the years 2001-2004 and then decreases. For both, 
Hybrid Hematology/Flow-Cytometry and Quantum-Dots related IP-Documents, after 
the year 2000, there is a convolutional continuous exponential increase of the filed IP-
applications. The results are clearly indicating the increasing involvement trend of 
Quantum-Dots, especially in modern Flow Cytometry. 
An overview of the trends in next generation nucleic acid and protein sequencing 
Identifying the functional elements encoded in a genome is one of the principal 
challenges in modern biology. Sequencing and Decoding Nucleic Acids and Proteins 
offer knowledge about the cellular functionality and process improving the 
biomedical aids available. Next Generation techniques provide credible and high 
throughput genetic information reducing cost and collection time. 
Classical sequencing methods have evolved by exploiting the overall evolution of 
technology in different fields such as imaging microscopy, chemistry and 
biochemistry, bioinformatics and biotechnology, computing and data storage. Pioneer 
conventional methods (1st Generation Sequencing) comprised of Auto-radiography, 
Chain reaction termination, Capillary electrophoresis, Edman degradation and Mass 
Spectrometry. 
 
Table 2. Important Next Generation Sequencing (NGS) methods. 
Next Generation Sequencing methods Next Generation Sequencing methods 
Shotgun-PCR 
Nanopore and Ion Semiconductor Sequencing 
(ISFET)  
Pyrosequencing Tandem Mass spectrometry 
LASER-linked Polymerase Colony 
(Polony) 
Membranes for solid phase 
Real time single molecule sequencing Chemical degradation in the Gas phase 
Reversible terminators MALDI mass spectrometry 
Sequencing by Oleg Ligation 
Detection 
Mass labeling reagents 
 
 
Next Generation Sequencing (NGS) techniques have evolved taking advantage of the 
overall evolution of Molecular Biology, ICT and micro/nano Technologies. The most 
important NGS methods are displayed in Table 2. The numbers of Next Generation 
Nucleic Acid and Protein sequencing methods related IP-Docs, filed per year during 
the period 1977-2013, are presented in Figure 14. 
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Figure 14. Numbers of Next Generation Nucleic Acids and Peptides Sequencing methods related               
IP-Docs filed per year during the period 1977-2013. 
 
The search concerning Nucleic Acid sequencing reveals a strong trend of IP-Docs 
related to ion semiconductor sequencing (e.g. US2010137143, WO2010016937, 
US2006246497), comprising of ISFET array sensors, DNA templates on micro-beads, 
H
+
-detection and multiple nanopore substrate arrays. Parallel template sequencing 
provides for rapid base reads and very low cost for equipment. Microscopy-based 
techniques, non-enzymatic methods, MALDI-TOF MS, Micro-fluidic Sanger 
sequencing, RNAP sequencing and in vitro virus high-throughput sequencing are 
considered as methods under development. 
     
Figure 15. NGS for Nucleic Acids (blue) and for Proteins (red) IP-Docs per applicant. 
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Figure 16. Numbers of  NGS for Nucleic Acids (blue) and for Proteins (red) related IP-Docs                     
per Patent Office of filing. 
 
The main trends in Protein sequencing remains the MALDII-ISD (In Source Decay) 
and US2010237238 and US8110795 are two interesting examples. Important 
properties include: 
 Peptide backbone fragmentation initiated by side-chain loss at cysteine residue. 
 MALDI yields mainly to singly-charged ions without abundant fragmentation. 
 Peptide mass finger-printing for the characterization of isolated proteins by the 
analysis of their      
   Peptide digest 
Finally, the promising nanopore-based protein sequencing are characterized by: 
 Single base resolution. 
 Unidirectionality. 
 Stability of the pore. 




We have presented an extended case-study focused on emerging in vitro 
Diagnostics Technology methods, as they are reflected on retrieved and evaluated 
Industrial Property Documents.  
More specific, we have presented first, the state-of-the-art and the perspectives 
of automatic Immunoassay Analyzers, second, we have followed the innovation 
patent-trail from Flow Cytometry to Quantum Dots applications in the in vitro 
Diagnostics of tomorrow and finally, we have provided an overview of the trends in 
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Next Generation Nucleic Acid and Protein Sequencing, all of them as depicted on 
numerous relevant, retrieved and processed Industrial Property Documents. 
We have the feeling that the developed IP-Doc based reviewing approach, 
offers a useful and convenient methodological tool for researchers, academic teachers 
and investors, to gain acquaintance and overview in any field of interest, supporting 
scientific and managerial decision making. 
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